Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Pediatric Hematology/Oncology
•
ALL
•
Hematology
How can the integration of MRD assessments into treatment protocols be optimized to improve risk stratification and therapy decisions in T-ALL?
Related Questions
When following current COG ALL protocols with the addition of two courses of blinatumomab to treatment for SR and HR patients, how frequently should surveillance bone marrow and MRD evaluations be performed?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
What is your standard for monitoring triglyceride level during therapy for ALL, particularly in regards to receiving pegaspargase?
What factors should be considered when deciding whether to omit radiation in pediatric/AYA patients receiving N+AVD, particularly regarding long-term outcomes and second malignancy risks?
How do you manage patients desiring home hospice but with severe thrombocytopenia and/or anemia due to advanced malignancy?
How would you proceed for a patient who has completed therapy for classic Hodgkin lymphoma with overall great disease response, but with new FDG avid lymph node on PET that is not amenable to biopsy?
What is the optimal timing for PET/CT to assess disease and treatment response with nivo + AVD?
How would you counsel patients with personal or family histories of autoimmune disease on immune checkpoint inhibitor therapy for Hodgkin lymphoma?
In an adult patient with asymptomatic, isolated neutropenia in whom you suspect a Duffy null phenotype, at what ANC or in what situations would you do a bone marrow to look for other etiologies of neutropenia?
How do you choose between the different available CAR-T cell therapy products for the treatment of relapsed Ph-negative ALL?
